Overcoming Integration Hurdles for Legacy Bioprocessing Equipment
How to bring older stainless-steel bioprocessing facilities into the era of real-time digital monitoring.
Stainless steel never expires, but the control systems built around it often do. Legacy bioprocessing equipment that has run reliably for decades represents enormous capital investment, yet retrofitting it with modern digital monitoring infrastructure remains one of the more technically demanding challenges in biopharmaceutical manufacturing. A clear-eyed strategy across sensors, software, and change control is required to close that gap without disrupting validated processes.
Key takeaways
- Legacy stainless-steel bioreactors were engineered before process analytical technology (PAT) frameworks existed, creating fundamental incompatibilities between hardware, communication protocols, and modern data infrastructure.
- Sensor retrofitting is achievable but requires careful selection of probe mounting configurations, calibration approaches, and materials that maintain sterility and good manufacturing practice (GMP) compliance.
- Software integration is typically the longest-lead item in a legacy upgrade, requiring middleware or protocol converters to bridge proprietary distributed control systems with modern data platforms.
- Any hardware or software modification to a validated legacy system triggers change-control obligations under guidelines and compliance requirements.
- A phased implementation strategy, beginning with at-line monitoring before advancing to closed-loop control, reduces regulatory risk and allows calibration models to mature on real process data.
Legacy bioprocessing equipment and the PAT integration gap
The Food and Drug Administration's (FDA) PAT framework, published in 2004, encouraged manufacturers to shift quality assurance from end-of-batch testing toward continuous, real-time measurement of critical process parameters and critical quality attributes. Most stainless-steel bioreactors commissioned before the mid-2000s were not designed with this philosophy in mind, and the gap between their native instrumentation and the demands of a PAT-enabled facility is structural rather than superficial.
These vessels typically measure a small set of variables directly: temperature, pH, dissolved oxygen, and agitation speed. The sensors are hardwired into proprietary distributed control systems that use closed, vendor-specific communication protocols, with data outputs going to historian databases or paper logs rather than to real-time process monitoring platforms. Adding new analytical capability to this infrastructure means working within or around architecture that was never intended to accommodate it.
As reviewed in a 2020 Trends in Biotechnology paper on PAT for monoclonal antibody (mAb) manufacturing, real-time spectroscopic and multivariate monitoring requires both the analytical hardware and the data pipelines needed to act on spectral information at process timescales.
Sensor retrofitting strategies for stainless-steel bioreactors
Physical sensor integration into legacy stainless-steel bioreactors is technically feasible, but the choice of probe configuration determines both the analytical capability and the regulatory complexity of the upgrade. Immersion probes inserted through existing nozzles require the vessel to retain its pressure and sterility ratings, with materials and sealing arrangements meeting the same biocompatibility standards as the original design.
Raman spectroscopy has become one of the most widely adopted spectroscopic tools for retrofitted in-line monitoring, because it delivers minimal water interference compared to near-infrared techniques and requires no sample extraction from the process stream. Vessel-mounted immersion probes and non-invasive flow cell configurations both serve this role: flow cells routed into a bypass or harvest stream require no vessel modification, making them well-suited to legacy facilities where physical changes carry a significant requalification burden. A 2022 study in Frontiers in Bioengineering and Biotechnology demonstrated non-invasive, in-line Raman monitoring of a perfusion cultivation. The researchers used a flow cell in the cell-free harvest stream, which generated glucose prediction models with a root-mean-square error of prediction of approximately 0.2 g/L across multiple bioreactor scales.
Facilities unable to accommodate vessel modifications can pursue at-line configurations, in which an automated sampling system withdraws a small aliquot, passes it through an external analyzer, and returns the data to the process control system. This avoids nozzle modifications entirely and is often the lower-risk starting point for legacy facilities, with in situ integration pursued once calibration models have been validated on real process data.
Retrofitting software infrastructure: data connectivity for legacy systems
Sensor hardware is the visible part of a PAT retrofit; the software infrastructure and communications layer is where integration projects most frequently stall. Legacy distributed control systems typically communicate over proprietary fieldbus protocols or early serial interfaces. This can mean they do not support the modern data exchange standards used by laboratory information management systems, manufacturing execution systems, or real-time process analytics platforms.
The Open Platform Communications Unified Architecture (OPC-UA) protocol has become the dominant interoperability standard for connecting industrial automation equipment to higher-level information systems. Most retrofitting projects use OPC-UA gateways or middleware servers to bridge the gap between legacy controllers and modern software. This approach avoids replacing the underlying control system, which would trigger full process revalidation, while enabling process data to be aggregated and made available to analytics software in near-real time.
Chemometric model maintenance adds a further layer of complexity. As reviewed in a 2025 Analytical Science Advances paper covering the downstream bioprocessing PAT landscape, spectroscopic PAT tools require ongoing multivariate calibration to remain accurate across changes in cell line, media formulation, and process conditions. A recent mAbs article on computational Raman for product quality identified laborious calibration as one of the primary barriers limiting wider deployment of Raman-based PAT at a commercial scale.
GMP change-control requirements for legacy bioprocessing equipment PAT upgrades
Modifications to validated legacy bioprocessing equipment carry regulatory obligations that must be scoped before any hardware or software changes are implemented. Under International Council Harmonisation (ICH) Q10 guidance, all changes to equipment, software, or control strategy require formal change-control evaluation to assess their impact on process performance and product quality. Where modifications touch electronic records, audit trails, or data management systems, 21 Code of Federal Regulations (CFR) Part 11 applies: any new software that creates or maintains GMP records must be validated, maintain secure and time-stamped audit trails, and restrict data modification to authorized personnel.
The principal change-control categories encountered in a legacy PAT integration project have varying classifications and regulatory implications (Table 1).
Table 1: Change-control categories and regulatory considerations for legacy bioprocessing PAT integration.
| Change type | Examples | Typical change-control classification | Regulatory implications |
| Hardware addition (no vessel modification) | External at-line analyzer, flow cell in bypass loop | Minor | Impact assessment; no requalification of vessel unless sterile boundary affected |
| Hardware addition (vessel modification) | New nozzle installation, immersion probe port | Major | Vessel requalification; pressure and sterility testing; materials review |
| Control system software update | OPC-UA gateway installation, data historian addition | Minor to moderate | Software validation per Good Automated Manufacturing Practice 5; 21 CFR Part 11 audit trail review |
| Control loop modification | Raman feedback into glucose feed control | Major | Process revalidation; regulatory filing may be required depending on market authorization status |
| Chemometric model update | New calibration model for revised media formulation | Moderate | Model validation; comparability data against reference method |
A phased approach reduces regulatory burden at each stage. Deploying at-line or on-line sensors in data-collection mode, without feedback control authority, typically qualifies as a minor or moderate change and allows process teams to build calibration confidence before advancing to the control integration that carries the highest regulatory weight. The quality by design principles codified in ICH Q8, Q9, and Q10 explicitly support this iterative accumulation of process knowledge as a foundation for enhanced control strategies.
Practical pathways for upgrading legacy bioprocessing equipment
Legacy bioprocessing equipment integration is best approached as a program with discrete phases that each deliver measurable analytical capability while maintaining the validated state of the process. The first phase focuses on data capture: installing sensors in non-invasive or bypass configurations, establishing OPC-UA or middleware connectivity, and building a process data archive to support chemometric calibration. The second phase advances to at-line monitoring with human-in-the-loop decision support, allowing model performance to be benchmarked against reference methods before the data carries control authority. The third phase, in situ closed-loop control, follows once validated models and regulatory acceptability have both been established.
The broader context of real-time process analytics in biopharmaceutical manufacturing is covered in the process analytics and industrial quality control hub, while the PAT in the modern lab secondary hub provides a detailed framework and tool context. Facilities evaluating spectroscopic sensor options for legacy retrofits will find comparative technical detail in the near-infrared vs Raman spectroscopy comparison for real-time bioprocess monitoring.
Legacy equipment does not have to remain analytically isolated. A structured integration program built around validated sensors, robust data connectivity, and disciplined change control can bring decades-old stainless-steel infrastructure into alignment with modern PAT expectations without compromising the process knowledge those systems hold.
This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
